Dr. Mark Buyyounouski, MD

Radiation Oncologist

Specialist

Stanford, CA

19 Years of Experience

Accepting patients

Affiliated with a Castle Connolly Top Hospital

Who is Dr. Buyyounouski, Radiation Oncologist in Stanford, CA?

Dr. Mark Buyyounouski, MD is a Radiation Oncologist, who primarily practices in Stanford, CA with 2 additional practice locations. He has been practicing for over 19 years and is board certified by the American Board of Radiology. Dr. Buyyounouski graduated from UMDNJ - NJMS and completed his residency at Fox Chase Cancer Ctr, Radiation Oncology; St Barnabas Med Ctr, Internal Medicine. Dr. Buyyounouski is fluent in English, and is currently seeing new patients. Dr. Buyyounouski’s practice accepts Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare, Aetna and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Buyyounouski’s office at (215) 728-6900.

What are Areas of Expertise for Dr. Buyyounouski?

Dr. Mark Buyyounouski, MD is a highly-rated, board-certified Radiation Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions or procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Buyyounouski empowers patients to confidently navigate their health journey, specializing in Brachytherapy, Clinical Trials, Genitourinary Cancer, Prostate Cancer, Stereotactic Radiosurgery, or comprehensive wellness support. Serving the Stanford/CA community, Dr. Buyyounouski is dedicated to enhancing lives through expert, patient-centered care.

Where did Dr. Buyyounouski go to medical school and complete their residency?

Residency: Fox Chase Cancer Ctr, Radiation Oncology; St Barnabas Med Ctr, Internal Medicine | Fox Chase Cancer Center
Medical School: Umdnj-New Jersey Med Sch- Newark Nj | UMDNJ - NJMS

Is Dr. Buyyounouski board certified in Radiation Oncologist?

Yes, Dr. Mark Buyyounouski, MD is board certified by the American Board of Radiology since 2006

What languages does Dr. Buyyounouski speak?

Dr. Buyyounouski and their clinical team can communicate with patients in the following languages:

English

What conditions does Dr. Buyyounouski treat?

As a Radiation Oncologist, Dr. Buyyounouski diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Buyyounouski. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.

Also known as:

Prostate Cancer
Prostate Cancer Treatment (PDQ®)
Prostatic Carcinoma
Prostate Gland Cancer
Malignant Prostate Tumor

ICD-10 Codes:

C61: Malignant neoplasm of prostate

Also known as:

Secondary Bone Cancer
Cancer in Multiple Lymph Node Regions
Cancer in Chest Lymph Nodes
Secondary Cancer (Other Specified Sites)
Bone Cancer
Cancer
Metastatic bone cancer
Cancer spread to bone
Bone metastases
Widespread Lymph Node Cancer
Metastatic Lymph Nodes in Multiple Areas
Multiregional Lymph Node Cancer
Metastatic Chest Lymph Node Cancer
Secondary Intrathoracic Lymphoma
Chest Lymph Node Metastasis
Metastatic cancer
Cancer spread to other organs
Cancer metastases

ICD-10 Codes:

C7951: Secondary malignant neoplasm of bone
C778: Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C771: Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C7989: Secondary malignant neoplasm of other specified sites

Also known as:

Secondary Cancer in Pelvic Lymph Nodes
Secondary Cancer in Head and Neck Lymph Nodes
Cancer
Metastatic Cancer to Pelvic Lymph Nodes
Pelvic Lymph Node Cancer Spread
Lymph Node Metastasis in Pelvis
Metastatic Cancer to Neck Lymph Nodes
Head and Neck Lymph Node Cancer Spread
Lymph Node Metastasis in Neck

ICD-10 Codes:

C775: Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
C770: Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck

Also known as:

Cancer Radiation Therapy
Radiation Therapy
Radiation Therapy to Treat Cancer
Radiation treatment for cancer
Oncology radiation
Radiotherapy

ICD-10 Codes:

Z510: Encounter for antineoplastic radiation therapy

Also known as:

Unspecified Illness
General sickness
Undiagnosed illness
Feeling unwell

ICD-10 Codes:

R69: Illness, unspecified

Which procedures does Dr. Buyyounouski perform as a Radiation Oncologist?

As a Radiation Oncologist, procedures performed by a Dr. Mark Buyyounouski may include:

For detailed information, please contact Dr. Buyyounouski's office.

Does Dr. Buyyounouski accept my insurance?

Dr. Buyyounouski accepts most major insurance plans. Important: Please call our office at (215) 728-6900 before your appointment to verify that your specific plan and network are accepted.

What insurance plans does Dr. Buyyounouski accept in Stanford, CA?

Dr. Buyyounouski in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.

Top Insurances

All Other Third Party
AllCare Health Plan
Blue Shield of California
Centene
CVS Health (formerly Aetna)
Department of Veterans Affairs
Medicaid
Medicare
Santa Clara Family Health Plan
UnitedHealthcare

View All Insurances

Where is Dr. Buyyounouski's office located?

Dr. Mark Buyyounouski's Primary Practice

300 Pasteur Dr

Stanford, CA 94305

(215) 728-6900

Get Directions

Dr. Mark Buyyounouski's Practice 2

875 Blake Wilbur Dr

Palo Alto, CA 94304

Get Directions

Dr. Mark Buyyounouski's Practice 3

5725 W Las Positas Blvd Ste 100

Pleasanton, CA 94588

Get Directions

Recognitions

Publications

Randomized trial of hypofractioted exterl-beam radiotherapy for prostate cancer.

Jourl of clinical oncology, 2013

Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?

JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2013

Validating the Interval to Biochemical Failure

JOURL OF CLINICAL ONCOLOGY, 2012

RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

DEVELOPMENT OF RTOG CONSENSUS GUIDELINES FOR THE DEFINITION OF THE CLINICAL TARGET VOLUME FOR

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Inflammatory Bowel Disease Is Not an Absolute Contraindication to Definitive Radiation Therapy

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

CT-MRI Fusion Uncertainty in Prostate Treatment Planning for Different Image Guidance Techniques

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

Toxicity and Biochemical Failure Following Image

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

Improved Outcomes in Men Treated With Adjuvant

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

Stratifying intermediate-risk patients for radiotherapy

TURE REVIEWS UROLOGY, 2013

Reduction of prostate intrafractiol motion from shortening the treatment time

PHYSICS IN MEDICINE AND BIOLOGY, 2013

A Novel Method for Predicting Late Genitouriry Toxicity After Prostate Radiation Therapy

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

Untitled Reply

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

In reply to Cheung.

Intertiol jourl of radiation oncology, biology, physics, 2013

Prospective Validation of Diagnostic Tumor Tissue Ki

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Primary Prostate Radiation Therapy: Where Are We Failing?

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Determints of Prostate Biopsy Positivity 2 Years After Radiation Therapy

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Do Testosterone Kinetics After Radiation Therapy (RT) Predict Biochemical Failure (BCF) for Low-

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Recursive Partitioning Alysis of Intermediate Risk Prostate Cancer Patients Identifies Subgroup

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

A Novel Methodology to Predict Late Uriry Toxicity Following Prostate Radiation Therapy

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Radiotherapy Treatment Planning for Testicular Seminoma

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Magnetic Resonce Spectroscopy of the Prostate: A Phantom Study of Metabolite Concentrations

MEDICAL PHYSICS, 2012

Effect of Gold Marker Seeds on Magnetic Resonce Spectroscopy of the Prostate

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Testicular Cancer Clinical Practice Guidelines in Oncology

JOURL OF THE TIOL COMPREHENSIVE CANCER NETWORK, 2012

Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Long-Term Survival After Radical Prostatectomy Versus Exterl

CANCER, 2011

INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTIL TOXICITY IN PATIENTS TREATED WITH ANDROGEN

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

PREDICTORS OF ANDROGEN DEPRIVATION THERAPY EFFICACY COMBINED WITH PROSTATIC IRRADIATION

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

The Impact of Gleason Scoring at a Comprehensive Cancer Center

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

A Nomogram Predicting 5

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Aspirin Use Reduces the Risk of Biochemical Failure

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

A Family History of Prostate Cancer is not Associated with Poorer Outcomes following Radiotherapy

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

VMAT Reduces Moderate to High Integral Dose When Compared to Conventiol IMRT

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a R

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Potential Treatment Margin Reduction for Prostate Treatment with RapidArc and VMAT

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Five Year Results of a R

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Genetic Polymorphisms of D Repair

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Prostate Bed Motion during Intensity Modulated Radiotherapy Treatment

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT

CADIAN JOURL OF UROLOGY, 2010

STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

RADIOTHERAPY PSA dir predicts long-term mortality

TURE REVIEWS CLINICAL ONCOLOGY, 2010

STEREOTACTIC BODY RADIOTHERAPY FOR PRIMARY MAGEMENT OF EARLY-STAGE

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high

BJU INTERTIOL, 2010

Young Age under 60 is not a Contraindication to Treatment with Definitive High Dose Exterl Beam

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Intermediate-risk Prostate Cancer Treated with High Dose Radiotherapy Alone or in Combition with

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Low Pretreatment PET SUV Predicts for Incre

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

The Stamp Test Delivers the Message on Erectile Dysfunction following High Dose IMRT

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Prelimiry Results of RTOG 0233

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

A Practical Strategy to Correct Prostate Rotation Reported by a 4D Localization System

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Interval to Biochemical Failure is Highly Prognostic for Distant Metastases

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Conventiol versus Hypofractioted IMRT

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

The Role of Adjuvant and Salvage Post-Prostatectomy IMRT or 3DCRT: The Fox Chase Experience

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

GAINS FROM REAL-TIME TRACKING OF PROSTATE MOTION DURING EXTERL BEAM RADIATION THERAPY

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Androgen Deprivation Therapy and Prostate Cancer Duration

JOURL OF CLINICAL ONCOLOGY, 2009

Optimal PET response following stereotactic body radiotherapy

JOURL OF THORACIC ONCOLOGY, 2009

Fil report of a phase I Dose Escalation Trial of Stereotactic Body Radiotherapy

JOURL OF THORACIC ONCOLOGY, 2009

RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Correlation of hypoxic prostate/muscle p(O2) (P/M P-O2) ratio

JOURL OF CLINICAL ONCOLOGY, 2009

Residual Prostate Cancer After Radiotherapy

JOURL OF UROLOGY, 2009

Initial PSA (iPSA) and Radiation Dose Predict for an Undetectable PSA following 3DCRT or IMRT for

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Defining Biochemical Failure following Salvage Radiotherapy

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

A Potential Outcomes Framework to Determine Whether Age

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Is MRI-based Week Three Post-implant Dosimetry Necessary following LDR Prostate Brachytherapy?

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Validating the Interval to Biochemical Failure

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Undetectable Post-treatment PSA following 3DCRT or IMRT Alone for Patients with Low or Intermediate

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Hypofractiotion for Prostate Cancer: Interim Results of a Randomized Trial

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

DOES TREATMENT DURATION AFFECT OUTCOME AFTER RADIOTHERAPY FOR PROSTATE CANCER?

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Comment on dose escalation and biochemical failure in prostate cancer

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

A comparison of acute

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Influence of local tumor control on distant metastases and cancer related mortality after exterl

JOURL OF UROLOGY, 2008

How can men destined for biochemical failure after androgen deprivation and radiotherapy be

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Percentage of biopsy cores positive for maligncy

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Commentary on dose escalation and biochemical failure in prostate cancer

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Predicting local persistence of intermediate

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Interval to biochemical failure highly prognostic for distant metastasis

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Low morbidity and excellent local control using image guided stereotactic body radiotherapy

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Gains from real-time prostate motion monitoring during exterl beam radiation therapy

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

The optimum duration of combition androgen deprivation therapy

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Androgen deprivation therapy plus hypofractioted prostate radiotherapy

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Radiation therapy for high risk prostate cancer

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Estimating gains in biochemical outcome from various durations of

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

PSA doubling time predicts for the development of distant metastases

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008

Prostate cancer risk assessment program: A 10-year update of cancer detection

JOURL OF UROLOGY, 2007

What dose of exterl-beam radiation is high enough for prostate cancer?

INTERTIOL JOURL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007

Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.

Journal of clinical oncology, 2013

Transurethral surgery

LANCET ONCOLOGY, 2013

Gleason Scoring at a Comprehensive Cancer Center: What's The Difference?

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013

Assessment of the American Joint Committee on Cancer Staging

CANCER, 2012

Validating the Interval to Biochemical Failure

JOURNAL OF CLINICAL ONCOLOGY, 2012

RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

DEVELOPMENT OF RTOG CONSENSUS GUIDELINES FOR THE DEFINITION OF THE CLINICAL TARGET VOLUME FOR

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Inflammatory Bowel Disease Is Not an Absolute Contraindication to Definitive Radiation Therapy

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

CT-MRI Fusion Uncertainty in Prostate Treatment Planning for Different Image Guidance Techniques

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

Toxicity and Biochemical Failure Following Image

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

Improved Outcomes in Men Treated With Adjuvant or Early Salvage Postprostatectomy IMRT

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

Stratifying intermediate-risk patients for radiotherapy

NATURE REVIEWS UROLOGY, 2013

Reduction of prostate intrafractional motion from shortening the treatment time

PHYSICS IN MEDICINE AND BIOLOGY, 2013

A Novel Method for Predicting Late Genitourinary Toxicity After Prostate Radiation Therapy

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

Untitled Reply

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013

In reply to Cheung.

International journal of radiation oncology, biology, physics, 2013

The impact of dose-escalated radiotherapy plus

CANCER, 2013

Prospective Validation of Diagnostic Tumor Tissue Ki

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Primary Prostate Radiation Therapy: Where Are We Failing?

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Determinants of Prostate Biopsy Positivity 2 Years After Radiation Therapy

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Do Testosterone Kinetics After Radiation Therapy (RT) Predict Biochemical Failure (BCF) for Low-

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Recursive Partitioning Analysis of Intermediate Risk Prostate Cancer Patients Identifies Subgroup

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

A Novel Methodology to Predict Late Urinary Toxicity Following Prostate Radiation Therapy

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Aspirin and Statin Nonuse Associated With Early Biochemical Failure After Prostate Radiation

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Prostate Bed Motion During Intensity-Modulated Radiotherapy Treatment

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Stamp Test Delivers Message on Erectile Dysfunction After High-dose Intensity

UROLOGY, 2012

Radiotherapy Treatment Planning for Testicular Seminoma

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

A survey of current clinical practice in permanent and temporary prostate brachytherapy

BRACHYTHERAPY, 2012

Magnetic Resonance Spectroscopy of the Prostate: A Phantom Study of Metabolite Concentrations

MEDICAL PHYSICS, 2012

How Certain Can the Real-Time Plan Predict the Post Dosimetry for Prostate Seed Implant?

MEDICAL PHYSICS, 2012

Effect of Gold Marker Seeds on Magnetic Resonance Spectroscopy of the Prostate

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Biochemical and clinical experience with real

BRACHYTHERAPY, 2012

Testicular Cancer Clinical Practice Guidelines in Oncology

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012

An evidence based review of proton beam therapy

RADIOTHERAPY AND ONCOLOGY, 2012

Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012

Young age under 60 years is not a contraindication to treatment with definitive dose escalated

RADIOTHERAPY AND ONCOLOGY, 2011

Long-Term Survival After Radical Prostatectomy Versus External

CANCER, 2011

INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

PREDICTORS OF ANDROGEN DEPRIVATION THERAPY EFFICACY COMBINED WITH PROSTATIC IRRADIATION

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

The Impact of Gleason Scoring at a Comprehensive Cancer Center on the Ability to Predict Recurrence

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

A Nomogram Predicting 5

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Aspirin Use Reduces the Risk of Biochemical Failure

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

A Family History of Prostate Cancer is not Associated with Poorer Outcomes following Radiotherapy

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

VMAT Reduces Moderate to High Integral Dose When Compared to Conventional IMRT

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Identification of a Single Nucleotide Polymorphism Related to Late Toxicity in a R

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Potential Treatment Margin Reduction for Prostate Treatment with RapidArc and VMAT

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Five Year Results of a R

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Genetic Polymorphisms of DNA Repair

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Prostate Bed Motion during Intensity Modulated Radiotherapy Treatment

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Treatment-related Side Effects And Quality Of Life Among Prostate Cancer Patients Treated With

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011

Implantation of electromagnetic transponders following radical prostatectomy for delivery of IMRT

CANADIAN JOURNAL OF UROLOGY, 2010

STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Androgen Deprivation Therapy in High-Risk Prostate Cancer

ONCOLOGY-NEW YORK, 2010

RADIOTHERAPY PSA nadir predicts long-term mortality

NATURE REVIEWS CLINICAL ONCOLOGY, 2010

STEREOTACTIC BODY RADIOTHERAPY FOR PRIMARY MANAGEMENT OF EARLY-STAGE

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy

BRACHYTHERAPY, 2010

Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high

BJU INTERNATIONAL, 2010

Young Age under 60 is not a Contraindication to Treatment with Definitive High Dose External Beam

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Intermediate-risk Prostate Cancer Treated with High Dose Radiotherapy Alone or in Combination with

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Low Pretreatment PET SUV Predicts for Incre

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

The Stamp Test Delivers the Message on Erectile Dysfunction following High Dose IMRT

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Preliminary Results of RTOG 0233

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

A Practical Strategy to Correct Prostate Rotation Reported by a 4D Localization System

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Interval to Biochemical Failure is Highly Prognostic for Distant Metastases

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

Conventional versus Hypofractionated IMRT

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

The Role of Adjuvant and Salvage Post-Prostatectomy IMRT or 3DCRT: The Fox Chase Experience

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010

GAINS FROM REAL-TIME TRACKING OF PROSTATE MOTION DURING EXTERNAL BEAM RADIATION THERAPY

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Androgen Deprivation Therapy and Prostate Cancer Duration

JOURNAL OF CLINICAL ONCOLOGY, 2009

Optimal PET response following stereotactic body radiotherapy

JOURNAL OF THORACIC ONCOLOGY, 2009

Final report of a phase I Dose Escalation Trial of Stereotactic Body Radiotherapy

JOURNAL OF THORACIC ONCOLOGY, 2009

Surveillance for Stage I Seminoma

ONCOLOGY-NEW YORK, 2009

RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Dosimetric comparison of stereotactic body radiotherapy using 4D CT

RADIOTHERAPY AND ONCOLOGY, 2009

Correlation of hypoxic prostate/muscle p(O2) (P/M P-O2) ratio

JOURNAL OF CLINICAL ONCOLOGY, 2009

Residual Prostate Cancer After Radiotherapy

JOURNAL OF UROLOGY, 2009

Race, Genetic West African Ancestry

CANCER PREVENTION RESEARCH, 2009

Initial PSA (iPSA) and Radiation Dose Predict for an Undetectable PSA following 3DCRT or IMRT for

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Defining Biochemical Failure following Salvage Radiotherapy

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

A Potential Outcomes Framework to Determine Whether Age

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Is MRI-based Week Three Post-implant Dosimetry Necessary following LDR Prostate Brachytherapy?

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Validating the Interval to Biochemical Failure

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Undetectable Post-treatment PSA following 3DCRT or IMRT Alone for Patients with Low or Intermediate

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

Hypofractionation for Prostate Cancer: Interim Results of a Randomized Trial

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009

DOES TREATMENT DURATION AFFECT OUTCOME AFTER RADIOTHERAPY FOR PROSTATE CANCER?